mTOR as Mediator of Insulin Sensitivity Study

• Status: Recruiting
• Trial end date: 2029-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

The study investigates the role of mTOR in mediating enhancement of muscle insulin sensitivity following a single bout of exercise.

This will be investigated in young healthy male subjects by administering the pharmacological mTOR inhibitor Rapamycin in a crossover blinded experimental setup known to enhance muscle insulin sensitivity following one-legged knee-extensor exercise.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Copenhagen
• Collaborator: Danish Diabetes Academy
• Treatments: Sirolimus

Criteria

Inclusion Criteria:

• Healthy persons (no known disease) without diabetes in the family

• No use of medications

• Non-smokers

• Men

• Age 22-35 years

• Physical activity level (VO2peak) between 30-50 mL O2/min/kg

• BMI between 18.0 and 25.0

Exclusion Criteria:

• Women

• Physical activity (e.g., running, cycling, fitness, etc.) above 6 hours a week.

• Persons who show signs of metabolic diseases, hematologic diseases, reduced liver function, human immunodeficiency virus (HIV), hepatitis, thyroid diseases or other signs of disease that may affect the outcome of the study or the study subject's wellbeing will be excluded.

• Acute sickness less than 2 weeks prior to study start.

• If disease appears or is identified and/or a need for medication arises after inclusion but before initiation of the study.

Disease during conclusion of the study